Aandeel Galapagos AEX:GLPG.NL, BE0003818359

quote:

moneymaker_BX schreef op 23 oktober 2020 19:56:

[...]

135

quote:

bezinteergebelegt schreef op 23 oktober 2020 20:21:

Heeft er iemand weer ff een teiltje voor me ?

quote:

Goudmijn64 schreef op 23 oktober 2020 20:02:

[...]

@ons aller Dietertje: dat zou mooi zijn.
verwacht je nog een overname?

quote:

geldmaker schreef op 23 oktober 2020 17:59:

Misschien iets meer vertrouwen getankt, maandag weer noordwaarts..

quote:

Mippert schreef op 23 oktober 2020 21:16:

Laag volume. Hier was het ook niet hoog. Ik denk dat de turbotikkers eruit zijn en dat GS zich long heeft ingekocht.

Nu op naar het uittikken van de shorts. Te beginnen maandag met de 111

De 111 en 112 hebben al geen laat meer

quote:

Mippert schreef op 23 oktober 2020 21:28:

108,70

het BROEIT!!!!!

En nog een halfuur te gaan.

quote:

HouLo Ken WiKo schreef op 23 oktober 2020 21:41:

[...]

Je zou dan toch juist geen bid verwachten?

Overigens denk dat dat we komende week hoger zullen gaan dan 111

quote:

Endless schreef op 24 oktober 2020 04:33:

email.seekingalpha.com/article/438112...

Galapagos Is A Buy Despite Setback In The Conclusion

Given how closely the two companies are tied together, one way to invest in Galapagos is to hold Gilead Science stock [which I do]. Gilead pays a dividend and has a large array of commercial therapies as well as an extensive pipeline. On the other hand, Gilead's stock price has been going mostly down for years. Since Galapagos will just begin to see commercial revenue this quarter, it is difficult to predict how filgotinib will fare in the competitive RA market. At the stock price of $123.68, Galapagos had a market capitalization of about $8.1 billion. Some revenue growth going forward is assumed in that market cap. I believe that would be justified if filgotinib eventually captures even 5% of the global RA market, which was near $58 billion in 2019, keeping in mind that Galapagos gets either royalties or a profit split.

The key for long-term investors is that filgotinib is just the start. In addition to the other potential drugs described in this article, Galapagos claims to be able to generate many more from its platform, and I find the claim credible. As always when enough clinical trials are involved, there will be some successes and failures, causing the stock price to dive or rise quickly at times. I have added Galapagos to the list of pharmaceutical companies I am considering buying, but it also has to compete with companies that are already in my portfolio that I think are undervalued and would like to own more of. Whether it is right for other investors depends on their individual investment strategies and assessments of the value of the pipeline.de

quote:

Mippert schreef op 23 oktober 2020 22:04:

[...]

Zolang de koersverandering geleidelijk gaat is er bied. Maar 'om ethische redenen' uche, uche is er dicht bij de stoploss geen laat meer.